Lomens-P0 (mixed extracts of Hordeum vulgare and Chrysanthemum zawadskii) regulate the expression of factors affecting premenstrual syndrome symptoms
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
BACKGROUND/OBJECTIVES Premenstrual syndrome (PMS) is a disorder characterized by repeated emotional, behavioral, and physical symptoms before menstruation, and the exact cause and mechanism are uncertain. Hyperprolactinemia interferes with the normal production of estrogen and progesterone, leading to PMS symptoms. Thus, we judged that the inhibition of prolactin hypersecretion could mitigate PMS symptoms. MATERIALS/METHODS Hordeum vulgare L. extract (HVE), Chrysanthemum zawadskii var. latilobum extract (CZE), and Lomens-P0 the mixture of these extracts were tested in subsequent experiments. The effect of extracts on prolactin secretion at the in vitro level was measured in GH3 cells. Nitric oxide and pro-inflammatory mediator expression were measured in RAW 264.7 cells to confirm the anti-inflammatory effect. Also, the hyperprolactinemic Institute for Cancer Research (ICR) mice model was used to measure extract effects on prolactin and hormone secretion and uterine inflammation. RESULTS Anti-inflammatory effects of and prolactin secretion suppress by HVE and CZE were confirmed through in vitro experiments (P < 0.05). Treatment with Lomens-P0 inhibited prolactin secretion (P < 0.05) and restored normal sex hormone secretion in the hyperprolactinemia mice model. In addition, extracts significantly inhibited the expression of pro-inflammatory biomarkers, including interleukin-1β, and -6, tumor necrosis factor-α, inducible nitric oxide synthase, and cyclooxygenase-2 (P < 0.01). We used high-performance liquid chromatography analyses to identify tricin and chlorogenic acid as the respective components of HVE and CZE that inhibit prolactin secretion. The Lomens-P0, which includes tricin and chlorogenic acid, is expected to be effective in improving PMS symptoms in the human body. CONCLUSIONS The Lomens-P0 suppressed the prolactin secretion in hyperprolactinemia mice, normalized the sex hormone imbalance, and significantly suppressed the expression of inflammatory markers in uterine tissue. This study suggests that Lomens-P0 may have the potential to prevent or remedy materials to PMS symptoms.
Abstract
BACKGROUND/OBJECTIVES Premenstrual syndrome (PMS) is a disorder characterized by repeated emotional, behavioral, and physical symptoms before menstruation, and the exact cause and mechanism are uncertain. Hyperprolactinemia interferes with the normal production of estrogen and progesterone, leading to PMS symptoms. Thus, we judged that the inhibition of prolactin hypersecretion could mitigate PMS symptoms. MATERIALS/METHODS Hordeum vulgare L. extract (HVE), Chrysanthemum zawadskii var. latilobum extract (CZE), and Lomens-P0 the mixture of these extracts were tested in subsequent experiments. The effect of extracts on prolactin secretion at the in vitro level was measured in GH3 cells. Nitric oxide and pro-inflammatory mediator expression were measured in RAW 264.7 cells to confirm the anti-inflammatory effect. Also, the hyperprolactinemic Institute for Cancer Research (ICR) mice model was used to measure extract effects on prolactin and hormone secretion and uterine inflammation. RESULTS Anti-inflammatory effects of and prolactin secretion suppress by HVE and CZE were confirmed through in vitro experiments (P < 0.05). Treatment with Lomens-P0 inhibited prolactin secretion (P < 0.05) and restored normal sex hormone secretion in the hyperprolactinemia mice model. In addition, extracts significantly inhibited the expression of pro-inflammatory biomarkers, including interleukin-1β, and -6, tumor necrosis factor-α, inducible nitric oxide synthase, and cyclooxygenase-2 (P < 0.01). We used high-performance liquid chromatography analyses to identify tricin and chlorogenic acid as the respective components of HVE and CZE that inhibit prolactin secretion. The Lomens-P0, which includes tricin and chlorogenic acid, is expected to be effective in improving PMS symptoms in the human body. CONCLUSIONS The Lomens-P0 suppressed the prolactin secretion in hyperprolactinemia mice, normalized the sex hormone imbalance, and significantly suppressed the expression of inflammatory markers in uterine tissue. This study suggests that Lomens-P0 may have the potential to prevent or remedy materials to PMS symptoms.
참고문헌 (38)
- Braverman PK, "Premenstrual syndrome and premenstrual dysphoric disorder", J Pediatr Adolesc Gynecol, 20, pp.3~12 (2007)
- Hong JP, "Prevalence, correlates, comorbidities, and suicidal tendencies of premenstrual dysphoric disorder in a nationwide sample of Korean women", Soc Psychiatry Psychiatr Epidemiol, 47, pp.1937~1945 (2012)
- Deuster PA, "Biological, social, and behavioral factors associated with premenstrual syndrome", Arch Fam Med, 8, pp.122~128 (1999)
- Hofmeister S, "Premenstrual syndrome and premenstrual dysphoric disorder", Am Fam Physician, 94, pp.236~240 (2016)
- Pearlstein TB, "Hormones and depression : what are the facts about premenstrual syndrome, menopause, and hormone replacement therapy?", Am J Obstet Gynecol, 173, pp.646~653 (1995)
- Schmidt PJ, "Premenstrual dysphoric disorder symptoms following ovarian suppression : triggered by change in ovarian steroid levels but not continuous stable levels", Am J Psychiatry, 174, pp.980~989 (2017)
- Yen JY, "Estrogen levels, emotion regulation, and emotional symptoms of women with premenstrual dysphoric disorder : the moderating effect of estrogen receptor 1α polymorphism", Prog Neuropsychopharmacol Biol Psychiatry, 82, pp.216~223 (2018)
- Osório FL, "Sex hormones and processing of facial expressions of emotion : a systematic literature review", Front Psychol, 9, pp.529~ (2018)
- Freeman ME, "Prolactin : structure, function, and regulation of secretion", Physiol Rev, 80, pp.1523~1631 (2000)
- Majumdar A, "Hyperprolactinemia", J Hum Reprod Sci, 6, pp.168~175 (2013)
- Wira CR, "The role of sex hormones in immune protection of the female reproductive tract", Nat Rev Immunol, 15, pp.217~230 (2015)
- Lennartsson AK, "Prolactin in response to acute psychosocial stress in healthy men and women", Psychoneuroendocrinology, 36, pp.1530~1539 (2011)
- Pałubska S, "Hyperprolactinaemia-a problem in patients from the reproductive period to the menopause", Przegl Menopauz, 16, pp.1~7 (2017)
- Seidlova-Wuttke D, "The premenstrual syndrome, premenstrual mastodynia, fibrocystic mastopathy and infertility have often common roots : effects of extracts of chasteberry(Vitex agnus castus)as a solution", Clin Phytoscience, 3, pp.6~ (2017)
- Borba VV, "Prolactin and autoimmunity", Front Immunol, 9, pp.73~ (2018)
- Wang X, "Water extract of Fructus Hordei Germinatus shows antihyperprolactinemia activity via dopamine D2 receptor", Evid Based Complement Alternat Med, 2014, pp.579054~ (2014)
- Li MX, "Anti-hyperprolactinemic effect of formula malt decoction, a Chinese herbal cocktail", Trop J Pharm Res, 14, pp.263~269 (2015)
- Kim AR, "The extract of Chrysanthemum zawadskii var. latilobum ameliorates collagen-induced arthritis in mice", Evid Based Complement Alternat Med, 2016, pp.3915013~ (2016)
- Kim KY, "Ethanol extract of Chrysanthemum zawadskii Herbich induces autophagy and apoptosis in mouse colon cancer cells through the regulation of reactive oxygen species", BMC Complement Altern Med, 19, pp.274~ (2019)
- Song HS, "Sorghum fermented by Aspergillus oryzae NK enhances inhibition of vascular inflammation in TNF-α-stimulated human aortic smooth muscle cells", Int J Vitam Nutr Res, 88, pp.309~318 (2018)
- Skwarło-Sońta K, "Prolactin as an immunoregulatory hormone in mammals and birds", Immunol Lett, 33, pp.105~121 (1992)
- Pereira Suarez AL, "Prolactin in inflammatory response", Adv Exp Med Biol, 846, pp.243~264 (2015)
- McCallum RW, "Metoclopramide stimulates prolactin secretion in man", J Clin Endocrinol Metab, 42, pp.1148~1152 (1976)
- Ben-Jonathan N, "Dopamine as a prolactin(PRL)inhibitor", Endocr Rev, 22, pp.724~763 (2001)
- Klein-Laansma CT, "Semi-individualized homeopathy add-on versus usual care only for premenstrual disorders : a randomized, controlled feasibility study", J Altern Complement Med, 24, pp.684~693 (2018)
- Verkaik S, "The treatment of premenstrual syndrome with preparations of Vitex agnus castus : a systematic review and meta-analysis", Am J Obstet Gynecol, 217, pp.150~166 (2017)
- Zamani M, "Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome", Acta Med Iran, 50, pp.101~106 (2012)
- Silva LG, "Rapid communication : prolactin and hydrocortisone impact TNFα-mediated mitogen-activated protein kinase signaling and inflammation of bovine mammary epithelial(MAC-T)cells", J Anim Sci, 95, pp.5524~5531 (2017)
- Cerqueira RO, "Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder : a systematic review", Arch Women Ment Health, 20, pp.713~719 (2017)
- Sharma JN, "Role of nitric oxide in inflammatory diseases", Inflammopharmacology, 15, pp.252~259 (2007)
- Moreno-Carranza B, "Prolactin regulates liver growth during postnatal development in mice", Am J Physiol Regul Integr Comp Physiol., 314, pp.R902~R908 (2018)
- Rondeau G, "Serum prolactin levels in a uremic child : effects of bilateral nephrectomy and kidney transplantation", NDT Plus, 4, pp.303~306 (2011)
- Gunin AG, "Effect of prolactin and dopaminergic drugs on uterine response to chronic estrogen exposure", J Endocrinol, 172, pp.61~69 (2002)
- Holm P, "A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits", Arterioscler Thromb Vasc Biol, 17, pp.2264~2272 (1997)
- Orkhon B, "Astragalus root induces ovarian β‑oxidation and suppresses estrogen‑dependent uterine proliferation", Mol Med Rep, 18, pp.5198~5206 (2018)
- Sugimoto Y, "Prostaglandin E receptors", J Biol Chem, 282, pp.11613~11617 (2007)
- Fischer DP, "Distribution and function of prostaglandin E2 receptors in mouse uterus : translational value for human reproduction", J Pharmacol Exp Ther, 373, pp.381~390 (2020)
- Koshikawa N, "Prostaglandins and premenstrual syndrome", Prostaglandins Leukot Essent Fatty Acids, 45, pp.33~36 (1992)